ZACKS·2025-10-09 16:55Core Insights - Revvity, Inc. (RVTY) is launching a program to enhance early detection of type 1 diabetes (T1D), impacting over nine million people globally, with support from Sanofi [1][8] - The initiative marks a strategic shift from Revvity's focus on genomic and rare diseases to large-scale clinical diagnostics [2][7] Product Development - The program centers on a 4-plex T1D autoantibody assay validated on Revvity's GSP instrument, utilizing both capillary dried blood spot and venous samples for early detection [3][7] - The GSP system's high-throughput capability addresses scalability challenges in routine clinical T1D screening, with regulatory submissions to the FDA and European IVDR indicating rapid commercialization plans [4][8] Market Performance - RVTY shares have decreased by 17.8% this year, contrasting with a 0.4% decline in the industry and a 15% increase in the S&P 500 Index [5] Strategic Collaboration - The partnership with Sanofi aims to expand access to Revvity's lab-developed tests globally while advancing regulatory-cleared diagnostics, enhancing clinical credibility and adoption [9][10] Industry Outlook - The global type 1 diabetes market is projected to grow at a CAGR of 6.4%, increasing from $16.97 billion in 2025 to $26.22 billion by 2032, driven by rising disease prevalence and improved diagnostic capabilities [11][12] - Revvity's collaboration with Sanofi positions the company to capitalize on the substantial market opportunity for early detection tools, potentially redefining T1D care standards [13]